3.00 mg tid

Maximum dosage

15.0 mg qid

2.00 mg qid

1.5 mg tid

8.00 mg tid

Source: From Ref. 15.

Source: From Ref. 15.

two trials used a double-blind design (19-21). These studies indicated a reduced frequency of dyskinesia and a trend toward less wearing off with bromocriptine. However, the larger number of dropouts in the bromocriptine group leaves these data subject to varied interpretations. In the treatment of early PD, bromocriptine may be beneficial in delaying motor complications and dyskinesia with comparable effects on impairment and disability in patients who tolerate the drug.

Numerous studies have demonstrated the benefits of bromocriptine in advanced PD. A double-blind, placebo-controlled, multicenter trial of bromocriptine in patients with motor fluctuations reported a 14% improvement in UPDRS activities of daily living (ADL), a 23.8% improvement in UPDRS motor scores and a 29.7% reduction in off time after nine months, with a mean daily dosage of 22.8 mg of bromocriptine (22).

Was this article helpful?

0 0

Post a comment